Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PhoreMost
Cambridge (Pampisford), England, UKphoremost.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead program for glioma treatment partnered with Sentinel Oncology expected to enter clinical trials. Six different E3 ligases in drug discovery. Achieved milestone in target discovery alliance with Boehringer Ingelheim.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesTargeted Protein Degradation (TPD)Degrader-based therapeutics
- Industry
- Biotech
02
Partnerships
Boehringer IngelheimOtsukaOxford BiomedicaXtalPiPOLARISqbNeoCuraSentinel Oncology
Beyond the preview
Go deeper on PhoreMost.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhoreMost.